SynsoryBio (YC W24) — "If-then" conditional logic for protein drugs
SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.
SynsoryBio is a Y Combinator company in the Winter 2024 batch. Its directory entry describes it as: "If-then" conditional logic for protein drugs. The founders listed are Elliot Tague (Founder), Nathan Tague (Founder) (Y Combinator directory entry, February 8, 2024).
Get an email when SynsoryBio changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.
Checked away from the directory entry. What is below does not come from the company's Y Combinator page.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Elliot Tague
Founder
I am a PhD and inventor in the fields of synthetic biology and protein engineering. I got my PhD from Boston University, spent time as a visiting graduate student in George Church's lab at Harvard, and worked in various biotech startups
Nathan Tague
Founder
I’m a co-founder of SynsoryBio, where we are creating therapeutics that sense-and-respond to disease. I have a background in synthetic biology and protein engineering with a PhD in Biomedical Engineering.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 65 companies held here in Healthcare › Therapeutics.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on SynsoryBio?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on SynsoryBio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on SynsoryBio covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind SynsoryBio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
